Lista de obras - Joaquín Arribas - Dominio Público Uruguay

A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers.

artículo científico publicado en 2012

ADAM17 (TACE) regulates TGFβ signaling through the cleavage of vasorin ⬇️

artículo científico publicado el 20 de diciembre de 2010

ADAM17 as a therapeutic target in multiple diseases.

artículo científico publicado en 2009

Cancer Therapeutic Resistance: Progress and Perspectives (April 7-8, 2016 - Barcelona, Spain).

artículo científico publicado en 2016

Cancer network activity associated with therapeutic response and synergism

artículo científico publicado en 2016

Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity

artículo científico publicado en 2019

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

artículo científico publicado en 2010

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

artículo científico publicado en 2013

Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib

scientific article published on 20 August 2018

Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.

artículo científico publicado en 2018

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

artículo científico publicado en 2004

Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.

artículo científico publicado en 2013

Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer.

artículo científico publicado en 2017

Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17.

artículo científico publicado en 2005

Effect of cellular senescence on the growth of HER2-positive breast cancers.

artículo científico publicado en 2015

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

artículo científico publicado en 2014

Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study

scientific article published on 28 December 2018

Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion

artículo científico publicado en 2014

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

artículo científico publicado en 2007

Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer

artículo científico publicado en 2018

GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells

scientific article published on 23 May 2022

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

scientific article published on 22 July 2016

Genetic alterations in the PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts

scientific article published on 27 March 2020

HER2 Fragmentation and Breast Cancer Stratification ⬇️

artículo científico publicado el 3 de agosto de 2010

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503

scientific article published on 04 March 2019

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

artículo científico publicado en 2014

High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.

artículo científico publicado en 2015

Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.

artículo científico publicado en 2015

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

artículo científico publicado en 2017

LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells

scientific article published on 28 August 2019

MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors

artículo científico publicado en 2019

MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer

artículo científico publicado en 2018

Matrix metalloproteases and tumor invasion

artículo científico publicado en 2005

Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts.

scientific article published on September 2016

Modulation of the Multicatalytic Proteinase Complex by Lipids, Interconversion and Proteolytic Processing ⬇️

artículo científico publicado el 1 de enero de 1993

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

scientific article published on 21 September 2018

N-terminal cleavage of proTGFalpha occurs at the cell surface by a TACE-independent activity.

artículo científico publicado en 2005

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

artículo científico publicado en 2008

Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis.

artículo científico publicado en 2017

PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells

artículo científico publicado en 2018

Pancreatic cancer heterogeneity and response to Mek inhibition

artículo científico publicado en 2017

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies

artículo científico publicado en 2015

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.

artículo científico publicado en 2014

Preclinical activity of PI3K inhibitor Copanlisib in Gastrointestinal Stromal Tumor

scientific article published on 05 May 2020

Pro-Tumor Necrosis Factor-α Processing Activity Is Tightly Controlled by a Component That Does Not Affect Notch Processing ⬇️

artículo científico publicado el 18 de septiembre de 1998

Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.

artículo científico publicado en 2018

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer.

artículo científico publicado en 2018

Recycling of cell surface pro-transforming growth factor-{alpha} regulates epidermal growth factor receptor activation.

artículo científico publicado en 2005

Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity

artículo científico publicado en 2017

Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence.

artículo científico publicado en 2015

Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.

artículo científico publicado en 2018

TGFβ-activated USP27X deubiquitinase regulates cell migration and chemoresistance via stabilization of Snail1

artículo científico publicado en 2018

TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells

artículo científico publicado en 2019

Targeting the EGF/HER Ligand-Receptor System in Cancer.

artículo científico publicado en 2016

The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration

artículo científico publicado en 2009

The protease MT1-MMP drives a combinatorial proteolytic program in activated endothelial cells

artículo científico publicado en 2012

Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer

scientific article published on 07 February 2019

Treating cancer's kinase 'addiction'.

artículo científico publicado en 2004

Who will benefit from treatment against EGFR?

scientific article published on 01 May 2005

p95HER2 and Breast Cancer ⬇️

artículo científico publicado el 22 de febrero de 2011

p95HER2-T cell bispecific antibody for breast cancer treatment

artículo científico publicado en 2018

Lista de obras de Joaquín Arribas

A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers.

ADAM17 (TACE) regulates TGFβ signaling through the cleavage of vasorin ⬇️

ADAM17 as a therapeutic target in multiple diseases.

Cancer Therapeutic Resistance: Progress and Perspectives (April 7-8, 2016 - Barcelona, Spain).

Cancer network activity associated with therapeutic response and synergism

Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation.

Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib

Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy.

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.

Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer.

Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17.

Effect of cellular senescence on the growth of HER2-positive breast cancers.

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study

Enhancing the Biological Relevance of Secretome-Based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer

GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

Genetic alterations in the PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts

HER2 Fragmentation and Breast Cancer Stratification ⬇️

HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.

Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells

MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors

MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer

Matrix metalloproteases and tumor invasion

Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts.

Modulation of the Multicatalytic Proteinase Complex by Lipids, Interconversion and Proteolytic Processing ⬇️

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

N-terminal cleavage of proTGFalpha occurs at the cell surface by a TACE-independent activity.

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis.

PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells

Pancreatic cancer heterogeneity and response to Mek inhibition

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.

Preclinical activity of PI3K inhibitor Copanlisib in Gastrointestinal Stromal Tumor

Pro-Tumor Necrosis Factor-α Processing Activity Is Tightly Controlled by a Component That Does Not Affect Notch Processing ⬇️

Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer.

Recycling of cell surface pro-transforming growth factor-{alpha} regulates epidermal growth factor receptor activation.

Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity

Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence.

Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.

TGFβ-activated USP27X deubiquitinase regulates cell migration and chemoresistance via stabilization of Snail1

TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells

Targeting the EGF/HER Ligand-Receptor System in Cancer.

The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration

The protease MT1-MMP drives a combinatorial proteolytic program in activated endothelial cells

Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer

Treating cancer's kinase 'addiction'.

Who will benefit from treatment against EGFR?

p95HER2 and Breast Cancer ⬇️

p95HER2-T cell bispecific antibody for breast cancer treatment